MirZyme Therapeutics is focused on the development and commercialisation of targeted therapeutics to prevent preeclampsia. 

 

MirZyme has several global patents granted. These relate to a pipeline of product offerings that address the unmet medical needs of patients with preeclampsia. Uniquely, MirZyme will be the first to provide targeted therapeutics with a companion diagnostic test for the disorder.

​

Professor Ahmed holds the position of Executive Chairman of the Board and oversees the vision and direction of the company. He has hand selected a great team to work within MirZyme, and collectively, they are developing a cure for preeclampsia.